Definition

Current Good Manufacturing Practice is the minimum regulatory standard that pharmaceutical manufacturers must meet to ensure drug substances and products are consistently produced and controlled to quality standards appropriate for their intended use. The "c" in cGMP is deliberate—it signals that the standard is not frozen. Manufacturers are expected to keep pace with evolving science, technology, and regulatory thinking. What was considered adequate ten years ago may not be sufficient today.

 

What cGMP Actually Governs 

cGMP reaches into every part of a pharmaceutical manufacturing operation. Facility design and environmental controls, equipment qualification, personnel training and hygiene, raw material testing and release, process documentation and execution, in-process monitoring, QC release testing, deviation management, CAPA systems, change control, and product quality reviews all of it falls within scope. The underlying principle is straightforward: quality cannot be tested into a finished product after the fact. It has to be built into the process from the start.

For API manufacturers specifically, ICH Q7 is the foundational guidance document. It defines when GMP controls apply across the manufacturing sequence typically from the point the Key Starting Material is introduced and sets expectations for documentation, process controls, and quality systems. In the US, FDA GMP regulations for drugs are codified in 21 CFR Parts 210 and 211. European manufacturers follow EU GMP Part II for active substances.

Regulatory agencies inspect manufacturing facilities periodically to verify compliance, and the consequences of non-compliance are serious: warning letters, import alerts, product recalls, or consent decrees. For CDMOs supplying global markets, maintaining inspection readiness across FDA, EMA, PMDA, and other regulatory bodies simultaneously is a meaningful operational capability, not something that can be switched on for an audit.
 

Related Topics

  • A Complete Guide to Commercial Manufacturing for Pharma Innovators 
  • Your Guide to CDMO Services: What Leading Pharma Teams Rely On
     

Related Terms

  • API CDMO
  • CMC (Chemistry, Manufacturing and Controls)
  • Drug Master File (DMF)

 

FAQs

  1. What is the difference between GMP and cGMP? 

    GMP is the general principle, a set of manufacturing standards. The "c" emphasises that these standards are current and must reflect the latest scientific understanding and technological capabilities. Compliance with how things were done in 2010 is not necessarily compliant today.

  1. Which guideline governs GMP for API manufacturing?

    ICH Q7 is the primary international standard. In the US, the FDA references relevant sections of 21 CFR Parts 210/211. The EU publishes Part II of its GMP Guidelines specifically covering active substances.

  1. At what point in API synthesis does GMP apply?

    ICH Q7 specifies that GMP applies from the introduction of the Key Starting Material. For earlier steps, the level of controls should increase progressively as the process approaches the final API. 

  1. How do CDMOs demonstrate ongoing GMP compliance?

    Through facility inspections by regulatory agencies, internal audit programmes, validated processes, complete and contemporaneous batch documentation, functioning deviation and CAPA systems, and annual product quality reviews.

  1. What are the consequences of a serious GMP finding?

    Warning letters, import alerts restricting supply to regulated markets, mandatory recalls, and in severe cases consent decrees that place manufacturing operations under direct regulatory oversight. Each outcome has significant commercial and reputational consequences.

 

Explore Neuland's cGMP-compliant API manufacturing capabilities across three dedicated facilities. Explore our CDMO Services